Latest Breaking News On - Jon congleton - Page 6 : comparemela.com

Mineralys Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Mineralys Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

United statesJon congletonCatalys pacificTanabe pharmaTom weibleExchange commissionElixir health public relationsUs centers for diseaseMineralys therapeutics incDrug administrationMineralys therapeuticsChief executive officerClinical highlightsInvestor relationsChronic kidney diseaseDisease control

Mineralys Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Mineralys Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesTom weibleTanabe pharmaJon congletonCatalys pacificExchange commissionDrug administrationMineralys therapeutics incElixir health public relationsUs centers for diseaseTherapeutics reports second quarterProvides corporateChief executive officerClinical highlightsInvestor relationsMineralys therapeutics

Mineralys Therapeutics (MLYS) Announces Expansion of Planned Phase 2 Trial of Lorundrostat Alone and in Combination with SGLT2 Inhibitor to Treat Patients with CKD

Mineralys Therapeutics (MLYS) Announces Expansion of Planned Phase 2 Trial of Lorundrostat Alone and in Combination with SGLT2 Inhibitor to Treat Patients with CKD
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

David rodmanJon congletonMineralys therapeutics incMineralys therapeuticsChief executive officerChief medical officer

Mineralys Therapeutics Announces Expansion of Planned Phase 2 Trial of Lorundrostat Alone and in Combination with SGLT2 Inhibitor to Treat Patients with Chronic Kidney Disease (CKD)

Mineralys Therapeutics Announces Expansion of Planned Phase 2 Trial of Lorundrostat Alone and in Combination with SGLT2 Inhibitor to Treat Patients with Chronic Kidney Disease (CKD)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesJon congletonTanabe pharmaCatalys pacificDavid rodmanDrug administrationExchange commissionUs centerMineralys therapeutics incMedia relationstom weibleelixir health public relationsphoneChief executive officerChief medical officerDisease controlMineralysmineralys therapeuticsMineralys therapeuticsLooking statementsmineralys therapeutics

Mineralys Therapeutics Presents Positive Lorundrostat Results from the Phase 2 Target-HTN Trial at ACC 23/WCC

Mineralys Therapeutics Presents Positive Lorundrostat Results from the Phase 2 Target-HTN Trial at ACC 23/WCC
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesDavid rodmanJon congletonCatalys pacificLuke laffinAmerican college of cardiologyMedia relationstom weibleelixir health public relationsphoneMineralys therapeutics incExchange commissionVascular thoracic instituteWorld congressAmerican collegeAnnual scientific sessionNew orleansChief executive officerEffective blood pressure lowering